

# Concise Synthesis of Anhydrovinblastine from Leurosine


Christophe Hardouin, Eric Doris,\* Bernard Rousseau, and Charles Mioskowski

CEA/Saclay, Service de Marquage Moléculaire et de Chimie Bioorganique, Bât. 547,  
Département de Biologie Joliot-Curie, 91191 Gif sur Yvette Cedex, France

eric.doris@cea.fr

Received January 15, 2002

## ABSTRACT




The Cp<sub>2</sub>TiCl-mediated deoxygenation of leurosine (1) afforded anhydrovinblastine (4) in good yield. Furthermore, as the reaction proceeded via a carbon-centered radical intermediate, this transient was also trapped by a hydrogen-atom donor to afford selectively reduced alkaloid 10.

Leurosine<sup>1</sup> (1) is one of the most abundant bisindole alkaloids isolated from the leaves of the Madagascan periwinkle *Catharantus roseus*. It was formerly classified in the family of Vinca alkaloids, which also included vinblastine (2), vincristine (3), and anhydrovinblastine (4) (Scheme 1).<sup>2</sup> Together with vinorelbine<sup>3</sup> (5) (Navelbine), a semisynthetic derivative currently on the market, these dimeric alkaloids

inhibit mitosis by binding to tubuline, thus allowing a broad spectrum of activity in the treatment of various carcinomas.<sup>2,4</sup> The synthesis of Navelbine (5) requires two steps: the biomimetic coupling of two monomers (catharanthine (6) and vindoline (7)) to afford anhydrovinblastine 4, followed by contraction of the latter's C' ring (Scheme 2).<sup>5</sup> Anhydrovinblastine is thus the key intermediate in the synthesis of the anticancer drug Navelbine. Herein, we would like to report a one-step procedure for the synthesis of anhydrovinblastine (4) starting from the parent alkaloid leurosine (1). Since the alkaloids 1 and 4 differ only by the presence of an epoxide on the "northern" portion of leurosine, the selective deoxy-

Scheme 1



Leurosine (1): n=2, R<sub>1</sub>= Et, R<sub>2</sub>-R<sub>4</sub>: -O-, R<sub>3</sub>= H, R<sub>5</sub>= Me

Vinblastine (2): n=2, R<sub>1</sub>= OH, R<sub>2</sub>= Et, R<sub>3</sub>=R<sub>4</sub>= H, R<sub>5</sub>= Me

Vincristine (3): n=2, R<sub>1</sub>= OH, R<sub>2</sub>= Et, R<sub>3</sub>=R<sub>4</sub>= H, R<sub>5</sub>= CHO

Anhydrovinblastine (4): n=2, R<sub>1</sub>= Et, R<sub>2</sub>-R<sub>3</sub>: (=), R<sub>4</sub>= H, R<sub>5</sub>= Me

Vinorelbine (5): n=1, R<sub>1</sub>= Et, R<sub>2</sub>-R<sub>3</sub>: (=), R<sub>4</sub>= H, R<sub>5</sub>= Me


(1) For an X-ray structure of leurosine methiodide, see: Hardouin, C.; Doris, E.; Rousseau, B.; Mioskowski, C.; Nierlich, M. *Acta Crystallogr.* **2000**, C56, 225–226.

(2) *The Alkaloids. Antitumor Bisindole Alkaloids from Catharantus Roseus (L.)*. Brossi, A., Suffness, M., Eds.; Academic Press: San Diego, 1990; Vol. 37.


(3) Langlois, N.; Guéritte, F.; Langlois, Y.; Potier, P. *J. Am. Chem. Soc.* **1976**, 98, 7017–7024.

(4) Zavala, F.; Guénard, D.; Potier, P. *Experientia* **1978**, 34, 1497–1499. Guéritte, F.; Pouilhès, A.; Mangeney, P.; Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y.; Potier, P. *Eur. J. Med. Chem.-Chim. Ther.* **1983**, 18, 419–424. Lobert, S.; Vulevic, B.; Correia, J. J. *Biochemistry* **1996**, 35, 6806–6814.

(5) Mangeney, P.; Andriamialisoa, R. Z.; Lallemand, J. Y.; Langlois, N.; Langlois, Y.; Potier, P. *Tetrahedron* **1979**, 35, 2175–2179. Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y.; Potier, P. *Tetrahedron* **1980**, 36, 3053–3060.



generation of the cyclic ether should thus provide direct access to anhydrovinblastine, as previously demonstrated by Attaur-Rahman (Scheme 3).<sup>6</sup>




Our strategy involves the utilization of a low-valent titanium species for the key deoxygenation step. Indeed, Nugent and RajanBabu reported that  $\text{Cp}_2\text{TiCl}$ <sup>7</sup> efficiently promotes the conversion of epoxides to the corresponding olefins under mild conditions.<sup>8</sup> Leurosine (**1**) was therefore reacted with  $\text{Cp}_2\text{TiCl}$  for 15 min at room temperature in THF. The low-valent titanium(III) complex was readily prepared by the in situ reduction of 2.5 equiv of  $\text{Cp}_2\text{TiCl}_2$  with 5 equiv of powdered zinc for 45 min.<sup>9</sup> The reaction produced anhydrovinblastine (**4**) cleanly in 70% yield; we identified

(6) Atta-ur-Rahman; Perveen, S. *J. Nat. Prod.* **1988**, *51*, 1271–1272.  
 (7) Gansäuer, A.; Bluhm, H. *Chem. Rev.* **2000**, *100*, 2771–2788. Li, J. *J. Tetrahedron* **2001**, *57*, 1–24.


**4** unambiguously by spectroscopic and chromatographic comparison with an authentic sample.

A postulated reaction mechanism is illustrated in Scheme 4. In the first step, the sequential single electron transfer from



$\text{Cp}_2\text{TiCl}$  to the oxirane and homolysis of the C–O bond generate the  $\beta$ -alkoxy radical **8**. The relative stability of the carbon-centered radical intermediate (for example, tertiary > secondary > primary) governs the regiochemistry of the ring opening. Upon reaction with a second equivalent of  $\text{Cp}_2\text{TiCl}$ , the  $\beta$ -alkoxy carbanion **9** results. Subsequent elimination of a titanium–oxo byproduct finally delivers deoxygenated anhydrovinblastine **4**.

The intermediacy of a radical species similar to **8** prompted us to trap this transient by a hydrogen-atom donor.<sup>10</sup> Such radical capture would produce a vinblastine-type alkaloid analogous to **10** by selective reduction of the epoxide (Scheme 5). To corroborate this hypothesis, a THF solution



of  $\text{Cp}_2\text{TiCl}$  was added dropwise to a mixture of leurosine (**1**) and a 10-fold excess of 2-methyl-2-propanethiol. Inverse addition of the titanium reagent to the epoxide was advanta-

(8) RajanBabu, T. V.; Nugent, W. A.; Beattie, M. S. *J. Am. Chem. Soc.* **1990**, *112*, 6408–6409. RajanBabu, T. V.; Nugent, W. A. *J. Am. Chem. Soc.* **1994**, *116*, 986–997. See also: Schobert, R. *Angew. Chem., Int. Ed. Engl.* **1988**, *27*, 855–856.

(9) Hardouin, C.; Chevallier, F.; Rousseau, B.; Doris, E. *J. Org. Chem.* **2001**, *66*, 1046–1048.

geous to minimize the competing deoxygenation to anhydrovinblastine. This furnished an alkaloid derivative to which we tentatively assign the structure of the bisindole **10**.<sup>11</sup> It should be noted that we obtained this product only in modest yield (11%) and as a single diastereomer, albeit with unknown stereochemistry of the ethyl group.

In conclusion, we have shown that the low-valent Cp<sub>2</sub>-TiCl efficiently deoxygenates leurosine to anhydrovinblastine.<sup>12</sup> A modified procedure was also applied to the synthesis

---

(10) Gansäuer, A.; Bluhm, H.; Pierobon, M. *J. Am. Chem. Soc.* **1998**, *120*, 12849–12859. Gansäuer, A. *Synlett* **1998**, 801–809.

(11) Kutney, J. P.; Honda, T.; Kazmaier, P. M.; Lewis, N. J.; Worth, B. R. *Helv. Chim. Acta* **1980**, *63*, 366–374.

(12) Szántay, C., Jr.; Balázs, M.; Bölskei, H.; Szántay, C. *Tetrahedron* **1991**, *47*, 1265–1274.

of a vinblastine-type alkaloid by selective reduction of the epoxide moiety of leurosine.

**Acknowledgment.** This work is part of a collaboration between Pierre Fabre Médicament/CEA-Direction des Sciences du Vivant. Dr. J. Albert Ferreira is gratefully acknowledged for reviewing this manuscript.

**Supporting Information Available:** Experimental procedures and spectral data for compounds **4** and **10**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL025560C